DefinitionThis section has been translated automatically.
Active substance that inhibits the formation of new blood vessels (angiogenesis, vasculogenesis).
Pharmacodynamics (Effect)This section has been translated automatically.
Monoclonal antibody from the group of monoclonal antibodies (IgG1). It binds to the Vascular Endothelial Growth Factor ( VEGF), a growth factor in the formation of new blood vessels. This blockage leads to an inhibition of vascular growth, especially in solid tumours.
You might also be interested in
Field of application/useThis section has been translated automatically.
Approval for metastatic colorectal carcinomas. Approval was granted for the combination with 5-fluorouracil/folinic acid or with 5-fluorouracil/folinic acid plus irinotecan. The efficacy in malignant melanoma is currently under review.
Undesirable effectsThis section has been translated automatically.
Wound healing disorders, hypertension, proteinuria, anaphylactic reactions, gastrointestinal perforations, bleeding tendencies, xerosis of the skin and exsiccation eczema, rare are acneiform exanthems which are frequently observed under therapy with EGF receptor antagonists (e.g. cetuximab) (see EGF receptor).
PreparationsThis section has been translated automatically.
Avastin®
LiteratureThis section has been translated automatically.
- Becker JC et al (2006) Molecularly targeted therapy for melanoma current reality and future options. Cancer 107: 2317-2327
- Gonzalez Cao M et al (2007) Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab. Clin Transl Oncol 9: 119-120
- Kowalzik L et al (2007) Xerosis and desiccation eczema under the therapy of a metastasized adenocarcinoma with monoclonal anti-VEGF antibody bevacizumab (Avastin). Act Dermatol 33: 385-387
Prof. Dr. med. Peter Altmeyer